Academic Literature

Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs

The growth in spending on cancer drugs can be attributed primarily to a unique legislative and regulatory framework that shields such drugs from the strategies that Medicare typically uses to hold down prices.
Originally published on 02/05/2009 in The New England Journal of Medicine

Fifteen years ago, the only commonly used cancer drug on the market that cost more than $2,500 per month was paclitaxel (Taxol, Bristol-Myers Squibb). Today, new cancer drugs cost many times that amount.

Spending on cancer drugs has risen faster than spending in many other areas of health care, in part because of rising prices and increased rates of use. For Medicare, spending on Part B drugs - a category dominated by drugs used to treat cancer - increased 267% from 1997 to 2004 as compared to the rise in overall Medicare spending of 47% during the same time.

There are a few major strategies Medicare uses to rein in spending: controlling utilization through determination of coverage, drug interchangeability, and through third parties. However, laws, regulations, and court rulings prevent Medicare from effectively managing increasing costs of cancer therapies. For instance, Medicare requires coverage of all or substantially all cancer therapies, which limits Medicare's ability to have discretion over coverage for Part B and Part D drugs (for plan sponsors). Price competition through interchangeability for a blended reimbursement is not applicable due to the strict standards of determining how a drug is multi-source, which excludes cancer drugs. Similarly, Least-Costly-Alternative (LCA) reimbursement and competitive bidding processes are restricted when cancer drugs are considered sole-source.

Read the full article here.


Research & Insights

We conduct non-partisan, independent research, and make our work accessible and informative to policymakers and the general audience alike. Browse our featured research or explore our work by article type.

Production Plus Profit Pricing (P-quad) FAQ
What A Waste! The National Academy Of Medicine’s Report On…
Why Congress should not follow the National Academy of Science, Engineering, and Medicine’s recommendation to remove the JW modifier.
Health Affairs Blog 07/09/2021
Medicare Must Study Unproven, Expensive Alzheimer’s Drug
Medicare cannot indiscriminately cover the cost of Aduhelm for the treatment of Alzheimer's disease without first evaluating whether it truly works.
Bloomberg Opinion 06/15/2021
Value-Based Management of Specialty Drugs: Practical Considerations and Implications for…
Not all approaches are suited to meeting policy makers and health plans’ goals of managing specialty drugs based on their value. Researchers conducted a qualitative study with Blue Cross Blue Shield plans interested in implementing value-based specialty pharmacy management to observe the plans’ objectives, strategies, and factors influencing their ability to execute on these strategies.
AJMC 05/13/2021
The Drugs at the Heart of Our Pricing Crisis
The US drug pricing system is broken, but not irreparable. For large-molecule biologic drugs, enter: Production Plus Profit Pricing (P-quad, pronounced like Ahab's seagoing vessel).
NYTimes 03/15/2021
Biosimilars: Market Changes do not equal policy success
Numerous articles and reports have trumpeted biosimilar market growth, but it's critical we do not lose sight of the sole objective for creating the biosimilar market: to reduce the cost of older biologic drugs for society and taxpayers.
Drug Pricing Lab 03/15/2021
Instead of debating 'first-shot' vs 'set-aside' vaccine approaches, hospitals' study…
Hospitals could start studies of their own employees to answer important questions, including whether the first-shot approach has downsides when compared to the set-aside strategy.
STAT 01/04/2021
After 4 Years of Trump, Medicare and Medicaid Badly Need…
Many promising ideas won't work as expected, and that's all the more reason for CMS to evaluate how medical care is delivered to its patients.
NYTimes 12/01/2020
Trump's Drug-Pricing Ideas Would Cost Taxpayers a Bundle
Meanwhile, pharmaceutical companies would stand to make a lot more money.
Bloomberg Opinion 09/29/2020
We can't tackle the pandemic without figuring out which Covid-19…
There may be several Covid-19 vaccines by winter, but there will also need to be a study comparing the viruses to one another as part of rolling out widespread vaccination.
STAT 09/24/2020
CMS's Proposed Medicaid Best Price Loophole for Value-Based Purchasing of…
The administration has proposed a loophole in the Medicaid Best Price rules that would dismiss linking the drug's effectiveness to its price.
HA Blog 07/06/2020
The Science on Coronavirus is Topsy-Turvy. That's Fine.
Urgency demands patience, because advancement is always a product of missteps.
NYTimes 04/30/2020
The Challenge

Launch Price Tracker


The Challenge — MERGE WITH NANCY

Stay up to date on our work and news